Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

The company remains in cost-cutting mode. On Thursday, FedEx said that its operating results improved in the second quarter, ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Nike CEO Elliott Hill said the Dow Jones giant is in the "middle innings of our comeback" after topping Q2 estimates.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Over 500 industry leaders gathered at the Dublin Royal Convention Centre to celebrate excellence in Ireland’s pharma sector ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...